Elevated TOP2A expression in ependymoma has not been reported previously; however, etoposide, a TOP2A inhibitor, has been used to treat recurrent ependymoma with very modest clinical results, likely because the agent has meager CNS penetration [47–49]. Here, TOP2A is linked to ependymoma.